You are here: Industry Insights > Immuno-Oncology

News List

Immuno-Oncology: Current Market Landscape and Future Trends（1） Neeta Ratanghayra
September 18, 2024
Immune Checkpoint Inhibitors & Challenges and Future Directions.
MIMETAS and Astellas Enter into Strategic Partnership on Immuno-Oncology PharmaSources
April 04, 2023
MIMETAS, a global leader in human disease modeling announces that it has entered into a strategic partnership with Astellas Pharma Inc., a global pharmaceutical company.
Sanofi to acquire immuno-oncology firm Amunix for $1bn Pharmaceutical-Technology
December 23, 2021
Sanofi has signed an agreement for the acquisition of immuno-oncology firm Amunix Pharmaceuticals for nearly $1bn in upfront payment.
GV20 Oncotherapy Completes Series B Financing to Advance Pipeline into the Clinic and Expand Immuno-Oncology Drug Discovery Platform prnasia
October 18, 2021
GV20 Oncotherapy, a biotechnology company with unique expertise in novel target identification and antibody drug discovery in immuno-oncology, today announced the completion of its Series B financing.
iBio Expands Immuno-Oncology Pipeline in AI Partnership with RubrYc Therapeutics firstwordpharma
August 26, 2021
iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company" today announced that it has signed a definitive worldwide exclusive license agreement with RubrYc Therapeutics, Inc., ("RubrYc") for RTX-003, an immunotherapy candidate targeting regulatory T cells (Tregs).
MAIA Biotechnology Appoints Joseph F. McGuire as CFO and Provides Corporate Update firstwordpharma
August 18, 2021
MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs ("MAIA"), announced today that it has appointed Joseph F. McGuire as Chief Financial Officer.
TherapeuticsMD Appoints Hugh O’Dowd as President firstwordpharma
August 10, 2021
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced the appointment of Hugh O'Dowd as President.
South-Korean biotech Y-Biologics and French mid-pharma Pierre Fabre enter into a worldwide exclusive license agreement in the highly innovative field of immuno-oncology prnasia
July 06, 2021
The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre have entered into a license agreement granting worldwide exclusive rights to Pierre Fabre to develop and commercialize a family of human antibodies generated ...
Human trials for world's first AI-designed immuno-oncology drug pharmatimes
April 13, 2021
Exscientia has announced that the world's first artificial intelligence (AI)-designed molecule for immuno-oncology has entered human clinical trials.
Immunogenesis Contracts ProBioGen for Development and Large-Scale Manufacturing Services b3cnewswire
March 25, 2020
ProBioGen AG today announced that Immunogenesis, Inc., a spin-off of the MD Anderson Cancer Center, University of Texas, has signed a Service Agreement for Cell Line Development, Process Development and GMP Manufacturing in 1,000 L bioreactor scale for th

Previous page 1 2 3 4 5 6 7 8 9 10 Next page